Celestra Health Systems

What Celestra Health Systems does

Celestra Health Systems is a privately held Canadian health-technology company, founded in 2021 and headquartered in Ottawa, with a regional office in Newport, Wales. The company has developed a cloud-based gait analysis platform designated by the FDA as a Class II Software as a Medical Device. The platform combines proprietary smart insoles (equipped with gyroscopes, accelerometers, and pressure sensors) with a patient-facing smartphone app, a cloud-based clinician web portal, and in-house AI/ML algorithms that measure more than 400 gait parameters at up to 200 measurements per second, aggregated into a composite 0–100 walking quality score. The primary clinical use case is continuous, real-world monitoring of patients with neurological conditions such as Multiple Sclerosis and Parkinson's Disease, where the platform claims to detect disease progression within 3 months versus roughly 12 months for standard clinical scales such as the EDSS and Timed 25-Foot Walk.

The company serves three primary customer segments: global pharmaceutical firms (using the platform as a clinical-trial endpoint and digital biomarker for drug efficacy assessment), research institutions (for gait biomarker validation and publication), and healthcare providers (for prescription-based clinical gait monitoring of patients in their natural environment). Its go-to-market is enterprise field sales combined with presence at major neurology conferences (CMSC, ECTRIMS, AAN), and distribution is prescription-driven with reimbursement through health insurance or government health plans. Clinical evidence is generated through 9 ongoing trials in 4 countries (US, UK, Germany, Canada), in collaboration with academic centers including Harvard Medical School, Technical University of Dresden, the Ottawa Hospital Research Institute, Barts Health, and Duke, and with pharma partners such as Sanofi on a CIDP study.

Celestra is controlled by Wesley Clover International, a private global investment firm with over $1B in assets under management, which provides the primary capital backing. The company employs 1–10 people, is pre-revenue or sub-$1M in disclosed revenue, and is currently pursuing ISO 13485 certification and FDA QSR/QMSR compliance to convert its existing Class II designation into a fully certified commercial quality system. Leadership consists of CEO Bruce Ford, a former senior executive of a NASDAQ-listed software firm.

Name

Celestra Health Systems

Legal name

Celestra Health Systems

Website

https://celestrahealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Celestra Health Systems is an Ottawa-based health-technology company that markets an FDA Class II cloud-based gait analysis platform, using smart insole sensors and proprietary AI, to monitor patients with neurological conditions such as MS and Parkinson's for pharmaceutical firms, research institutions, and healthcare providers.

Ownership category

akta.pro rank

Product category

Digital Health Gait Analysis

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Gait analysis software
• Digital biomarker platform
• Wearable smart insoles
• Neurological disease monitoring
• Clinical gait measurement

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Gait Measurement Platform Subscription: Cloud-based software platform providing continuous gait monitoring and analysis for patients with neurological conditions. Requires prescription and is covered by health insurance plans.
2. Smart Insole Hardware: Wearable smart insoles equipped with proprietary sensors sold as part of the platform deployment.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Celestra Health Systems sells an FDA-designated Class II cloud-based gait analysis platform that uses proprietary AI algorithms and wearable smart insole sensors to continuously measure walking quality in patients with neurological conditions such as Multiple Sclerosis and Parkinson's Disease. The solution includes smart insoles, a patient smartphone app, and a clinician web portal that aggregate 400+ gait metrics into a composite walking quality score for earlier detection of disease progression. Customers include global pharmaceutical firms, research institutions, and healthcare providers, with distribution via prescription and health insurance coverage.

Product overview

Celestra Health Systems offers a cloud-based gait analysis platform designated by the FDA as a Class II medical device. The platform consists of smart insoles equipped with sensors (gyroscopes, accelerometers, pressure sensors) paired with a proprietary composite walking score algorithm. The core product is the "Gait Lab in a Shoe" platform, which includes wearable smart insoles for patients, a smartphone app for patient data visualization, and a cloud-based clinician web portal for healthcare providers. The system measures over 400 gait metrics and aggregates them into a single walking quality score (0-100) to track disease progression for neurological conditions such as MS and Parkinson's.

Differentiator

Problem solved

Functional benefit

Products and services

• Gait Lab in a Shoe Platform FDA-designated Class II Software as a Medical Device platform that uses proprietary AI algorithms to objectively measure walking quality based on data collected by wearable smart insoles (gyroscopes, accelerometers, pressure sensors), smartphones, and smartwatches. It is prescribed to patients with MS, Parkinson's, and other neurological conditions and delivers clinician-facing insights via a secure web portal.
• Celestra Health Smart Insole Wearable insole sensors equipped with gyroscopes, accelerometers, and pressure sensors that automatically wake when movement is detected and capture up to 200 measurements per second across 400+ gait parameters, transmitting data to the Celestra Health cloud. Patients place the insoles in their everyday footwear for automatic, continuous gait monitoring.
• Celestra Health Smartphone App Patient-facing mobile application installed on the patient's personal smartphone that receives data from Celestra smart insoles and delivers personalized walking quality scores and insights. It supports automatic data collection when insoles detect movement and is designed for long-term usability in everyday footwear.
• Clinician Web Portal Secure cloud-based web portal used by clinicians and healthcare providers to view patient walking quality trends, track treatment effectiveness over time, and receive automatic notifications when signs of significant disease progression are detected. It presents low-level gait metrics aggregated into a composite 0-100 walking quality score.

Quantifiable outcome

• Detects disease changes within 3 months that only appear in clinical assessments after 12 months
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, secondary and minor.

• University of OttawacoreStrategic or Co-development PartnerAcademic research collaboration involving multiple studies including validation of instrumented shoe insole framework, gait activity recognition, and clinical practice cost-effectiveness research.
• Ottawa Hospital Research Institute (OHRI)coreStrategic or Co-development PartnerClinical research collaboration on real-world gait monitoring validation studies and MS progression research.
• Brigham and Women's Hospital / Harvard Medical SchoolcoreStrategic or Co-development PartnerCollaboration with Professor Tanuja Chitnis (Chief, Division of Neuroimmunology) on MS research and gait measurement validation.
• Technical University of Dresden (TUD)coreStrategic or Co-development PartnerCollaboration with Professor Tjalf Ziemssen (Director, Center of Clinical Neuroscience) on MS clinical practice research.
• The Ottawa HospitalcoreStrategic or Co-development PartnerClinical research collaboration including MS community events and gait monitoring studies with Dr. Mark Freedman and Dr. David Grimes.
• Duke University Medical CentersecondaryStrategic or Co-development PartnerClinical research collaboration on CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) gait measurement study.
• Barts Health NHS TrustsecondaryStrategic or Co-development PartnerCollaboration with Dr. Sharmilee Gnanapavan on neurology research and clinical practice.
• SanofisecondaryStrategic or Co-development PartnerCollaboration on CIDP study exploring smart insole technology for tracking gait quality in people with CIDP in real-world settings.
• International Progressive MS AlliancesecondaryStrategic or Co-development PartnerSelected as one of five global digital biomarker firms to attend the 3-day digital workshop, recognized for technologies with potential to make real difference for people living with Progressive MS.
• Canadian Entrepreneurs in Life Sciences (CELS)minorGTM or Marketing PartnerParticipated in Showcase in the Valley investor event in San Francisco organized by CELS, a non-profit connecting Canadian health sciences startups with investor networks.
• World-class Team of NeurologistscoreStrategic or Co-development PartnerGlobal team of neurologists from Harvard Medical School (US), Bart's Health / Royal London Hospital (UK), University of Edinburgh (UK), Technical University of Dresden (Germany), and The Ottawa Hospital (Canada) consulted throughout platform design process.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• APDM Wearable Technologies (Clario): Now part of Clario, APDM provides wearable sensors and software for gait and movement analysis in clinical trials for neurological conditions including MS and Parkinson's. Most direct competitor to Celestra in objective gait endpoints for pharma trials.
• Kinesis Health Technologies: Develops wearable sensor-based gait and balance assessment tools for fall risk and neurological conditions, with clinical-grade mobility analytics comparable to Celestra's platform.
• ProtoKinetics: Manufacturer of the Zeno Walkway and PKMAS software for gait analysis in clinical and research settings, serving similar neurology and rehabilitation markets as Celestra.
• Great Lakes NeuroTechnologies: Develops wearable sensors and software for movement disorder monitoring (Parkinson's, essential tremor), with FDA-cleared Kinesia technology serving overlapping neurology customer segments.
• ActiGraph: Provider of wearable activity monitors and digital endpoint solutions for clinical trials and academic research, with comparable pharma and academic customer base for objective mobility measurement.
• Vivonoetics: Provides wearable sensor platforms (including ECG, respiration, and actigraphy) and analytical software for clinical research, with overlapping pharma trial endpoint capabilities for neurological and chronic disease studies.

Emerging players

• BioStamp (MC10): Wearable medical-grade sensor platform for continuous physiological and movement monitoring in clinical research, with overlapping use cases in neurological and mobility disorder trials.
• Byteflies: Belgian wearable health monitoring company focused on remote patient monitoring and clinical trial endpoints, with sensor-to-cloud architecture comparable to Celestra's gait platform.

Broad incumbents

• Movella (Xsens): Motion capture and inertial sensor company with clinical and research-grade gait/movement analysis capabilities, serving adjacent markets in clinical research, sports, and entertainment.
• Verily Life Sciences: Alphabet-owned precision health technology company developing digital biomarkers and wearable sensors across multiple disease areas including neurological conditions, representing a well-capitalized incumbent threat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/celestra-health

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celestra Health Systems